What Is Going On With Emergent BioSolutions Shares?
What Is Going On With Emergent BioSolutions Shares?
Emergent BioSolutions (NYSE:EBS) stock is trading higher on Thursday after the company announced the sale of its facility in Baltimore-Camden to Bora Pharmaceuticals.
Emergent Biosolutions (NYSE:EBS)股價在週四交易中上漲，此前該公司宣佈將其在巴爾的摩 - 卡姆登的設施出售給寶瑞製藥。
What Happened: On Thursday prior to the market open, Emergent BioSolutions announced it entered into a definitive agreement with Bora to sell the site for about $30 million.
發生了什麼：在週四開市之前，Emergent Biosolutions宣佈與寶瑞達成了明確的協議，以約3000萬美元的價格出售該工廠。
Besides the acquisition of the site, about 350 Emergent employees are anticipated to join Bora.
除了收購該站點外，預計將有約350名Emergent員工加入寶瑞。
The Baltimore-Camden site is a drug product facility that has clinical and commercial non-viral finish services across four fill lines, including lyophilization, formulation development, and additional support services.
巴爾的摩 - 卡姆登站點是一家藥品生產廠，提供臨床和商業的非病毒塗層服務，包括凍幹、配方開發和其他支持服務。
"The decision to sell our Camden manufacturing facility is aligned with our multi-year plan to create a customer focused, leaner and more flexible organization, while we improve overall profitability and raise capital to reduce our debt," said Joe Papa, CEO at Emergent.
“出售我們的卡姆登製造設施的決定與我們的多年計劃相一致，這個計劃是爲了打造以客戶爲中心，更精簡、更靈活的組織，提高總體盈利能力並籌集資本以減少我們的債務，” Emergent的首席執行官Joe Papa表示。
The transaction is expected to close in the 2024 third quarter.
交易預計將在2024年第三季度結束。
Separately, Benchmark analyst Robert Wasserman maintains Emergent BioSolutions with a Buy and raises the price target from $5 to $8.
此外，Benchmark分析師Robert Wasserman將Emergent Biosolutions定爲買入，並將目標價格從5美元升至8美元。
EBS Price Action: At the time of writing, Emergent BioSolutions is trading 6.85% at $6.47 per data from Benzinga Pro.
EBS價格走勢：截至發佈本文時，Emergent Biosolutions每股交易價格爲6.47美元，上漲了6.85%，數據來自Benzinga Pro。
Image: Photo from Shutterstock.
圖像來源: 來自 shutterstock 的照片。
譯文內容由第三人軟體翻譯。